胡立德, 刘传峰, 李萍, 董冠宇, 刘新泳, 展鹏. SARS-CoV-2刺突蛋白抑制剂活性筛选方法研究进展J. 药学学报, 2024, 59(2): 298-312. DOI: 10.16438/j.0513-4870.2023-0507
引用本文: 胡立德, 刘传峰, 李萍, 董冠宇, 刘新泳, 展鹏. SARS-CoV-2刺突蛋白抑制剂活性筛选方法研究进展J. 药学学报, 2024, 59(2): 298-312. DOI: 10.16438/j.0513-4870.2023-0507
HU Li-de, LIU Chuan-feng, LI Ping, DONG Guan-yu, LIU Xin-yong, ZHAN Peng. Recent advances in drug screening methods of SARS-CoV-2 spike proteinJ. Acta Pharmaceutica Sinica, 2024, 59(2): 298-312. DOI: 10.16438/j.0513-4870.2023-0507
Citation: HU Li-de, LIU Chuan-feng, LI Ping, DONG Guan-yu, LIU Xin-yong, ZHAN Peng. Recent advances in drug screening methods of SARS-CoV-2 spike proteinJ. Acta Pharmaceutica Sinica, 2024, 59(2): 298-312. DOI: 10.16438/j.0513-4870.2023-0507

SARS-CoV-2刺突蛋白抑制剂活性筛选方法研究进展

Recent advances in drug screening methods of SARS-CoV-2 spike protein

  • 摘要: 严重急性呼吸综合征冠状病毒2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) 引起的新型冠状病毒感染(corona virus disease 2019, COVID-19) 对全球公共卫生和经济造成了前所未有的影响。SARS-CoV-2通过其表面的刺突蛋白与宿主细胞膜上的血管紧张素转换酶2相结合是入侵宿主细胞的关键步骤, 以刺突蛋白为靶标的小分子药物成为抗SARS-CoV-2研究的热点。活性筛选是小分子药物研发的关键步骤。鉴于此, 本文综述了SARS-CoV-2刺突蛋白小分子抑制剂的活性筛选方法, 以期为靶向刺突蛋白的抗病毒药物研发提供参考。

     

    Abstract: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a serious impact on global public health and the economy. SARS-CoV-2 infiltrates host cells via its surface spike protein, which binds to angiotensin-converting enzyme 2 on the host cell membrane. As a result, small molecules targeting spike protein have emerged as a hotspot in anti-SARS-CoV-2 drug research. Activity screening is an important step in seeking small molecule drugs. Therefore, this article aims to review the biological activity evaluation methods of small molecule inhibitors targeting SARS-CoV-2 spike protein, with the goal of laying the foundation for the discovery of new anti-SARS-CoV-2 drugs.

     

/

返回文章
返回